Evotec SE (EVT.DE)
- Previous Close
13.21 - Open
13.17 - Bid 13.33 x 105300
- Ask 13.34 x 169300
- Day's Range
12.98 - 13.45 - 52 Week Range
12.61 - 24.44 - Volume
694,213 - Avg. Volume
733,168 - Market Cap (intraday)
2.383B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.53 - Earnings Date Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.60
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
www.evotec.com5,086
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EVT.DE
Performance Overview: EVT.DE
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVT.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVT.DE
Valuation Measures
Market Cap
2.34B
Enterprise Value
2.31B
Trailing P/E
--
Forward P/E
62.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.85
Price/Book (mrq)
2.05
Enterprise Value/Revenue
2.81
Enterprise Value/EBITDA
-36.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.57%
Return on Assets (ttm)
0.17%
Return on Equity (ttm)
-8.02%
Revenue (ttm)
820.8M
Net Income Avi to Common (ttm)
-94.98M
Diluted EPS (ttm)
-0.53
Balance Sheet and Cash Flow
Total Cash (mrq)
613.37M
Total Debt/Equity (mrq)
51.61%
Levered Free Cash Flow (ttm)
-175.95M